← Open Payments lookup

NPI 1013929470: Open Payments

NPI 1013929470. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$3,582 in 185 payments from 18 companies in 2025. Trend: 2023 $4,592 · 2024 $5,939 · 2025 $3,582

Food & beverage: $3,570Education: $11
CompanyPaymentsAmount
Axsome Therapeutics, Inc.20$463
ABBVIE INC.20$386
Lundbeck LLC21$367
Alkermes, Inc.25$344
Neurocrine BioSciences, Inc.10$289
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)10$252
Vanda Pharmaceuticals Inc.8$216
Supernus Pharmaceuticals, Inc.19$208
Teva Pharmaceuticals USA, Inc.9$192
E.R. Squibb & Sons, L.L.C.9$191

Products named: Auvelity, VRAYLAR, ARISTADA, INGREZZA, CAPLYTA, FANAPT, Qelbree, REXULTI.